BridgeBio terminates effort to acquire remainder of Eidos Therapeutics
BridgeBio, which already owns about 66 percent of Eidos, had initially offered to buy the company in August, but the proposed deal was rejected. Eidos is developing a drug in the competitive ATTR space.